What action should clinicians take for women who are at increased risk for breast cancer regarding medications?

Clinicians should engage in decision-making about risk-reducing medications for women at increased risk for breast cancer. This approach is important because it allows for a collaborative dialogue between the clinician and the patient regarding the benefits and risks of such medications. It acknowledges the fact that individual circumstances, preferences, and potential side effects must be considered when making healthcare decisions.

Risk-reducing medications, such as selective estrogen receptor modulators (SERMs) or aromatase inhibitors, can offer significant benefits in lowering breast cancer risk for certain patients, but they may also come with side effects or other personal health considerations. By involving patients in the decision-making process, clinicians can help ensure that the chosen course of action aligns with the patient's values and preferences, ultimately leading to better adherence and satisfaction with the treatment plan.

This method recognizes the importance of informed consent and thoughtful communication in clinical practice, especially in the context of preventive strategies for individuals at higher risk.